Skip to main content
Premium Trial:

Request an Annual Quote

Geospiza Pockets $1M from NIH to Re-engineer Phrap

NEW YORK, March 19 - Geospiza on Tuesday said that the US National Institutes of Health has awarded it $1.1 million to "re-engineer" its Phrap gene-sequencing technology.


Geospiza and its research partner Southwest Parallel Software will use the cash to "improve Phrap's ability to use external information" to help researchers assemble gene sequences. These modifications will make the technology "better suited for high-throughput data processing," Geospiza said.


Phrap-based research has over the past few years expanded to include SNP and mutation discovery, expression analysis, bacterial sequencing, and confirmatory sequencing, the company said in a statement.


"Phrap was originally developed with a more narrow focus as a tool to assist genome centers sequencing cosmids," Todd Smith, president of Geospiza, said in the statement. "But people are using Phrap for new things now and the applications for [it] have increased...."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.